$NTRA

Chapman Steven Leonard sold $1.5M of NTRA

Chapman Steven Leonard (CEO AND PRESIDENT) sold 5,770 shares of Natera, Inc. (NTRA) at an average of $256.51 ($254.07–$260.49, $1.48M total) across 2 trades over 2026-07-27 to 2026-07-28 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Chapman Steven Leonard
Published Jul 30, 2026, 1:35 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 30, 2026, 2:01 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$NTRA
Neutral
high confidence
Mentioned
$NTRA
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NTRANeutralLow
01

Why it matters

The newest fact is the CEO’s disclosed open-market sale amount and timing under a 10b5-1 plan; it may slightly influence sentiment but does not change fundamentals based on the provided text.

02

Market read

Traders may note the insider sale for sentiment/positioning, but there is no new guidance, trial result, deal, or regulatory action in the text.

03

What to watch

The price range of the sale ($254.07 to $260.49) could coincide with normal trading volatility, and the net holdings after the sale (102,973 shares) suggests continued insider exposure.

Relevance 5/10Novelty 3/10Timing: SEC Form 4 filed late July, with sales executed 2026-07-27 to 2026-07-28.

Background

The article is an SEC Form 4 insider transaction disclosure for Natera, Inc. (NTRA).

Company-level read

Ticker impact

$NTRANeutralHigh confidence
Context

Natera CEO and President Chapman Steven Leonard sold about $1.48M of NTRA shares via a 10b5-1 plan across two open-market trades in late July.

Expected impact

Likely limited, short-lived sentiment impact; no clear directional signal beyond routine 10b5-1 selling.

Evidence & confidence

The filing is a Form 4 insider transaction with a stated pre-arranged 10b5-1 plan, and it provides no new operational, financial, or regulatory catalyst.

Market effects

Minimal. The disclosure is company-specific and does not introduce a sector-wide catalyst.

None indicated.

None indicated.

Counterpoint

Because the sale is pre-arranged under 10b5-1, the market may overreact; the transaction may not reflect negative expectations.

Key entities

  • Natera, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • Chapman Steven Leonard

    CEO and President who sold shares under a pre-arranged 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$NTRAMed

Jim Cramer Calls Natera (NTRA) “a Promising Story”

Natera (NTRA) reported Q2 revenue of $752.8M, up 37.7% YoY, and raised its 2026 revenue forecast. Jim Cramer called it a promising precision medicine platform but advised waiting for a pullback due to valuation concerns. The company faces competition and regulatory risks, with a net loss of $67M in Q2.

$MRNAHighAI 8/10

Why Moderna's Cancer Vaccine Matters To Investors

Moderna (MRNA) and Merck (MRK) reported successful late-stage trial results for a personalized mRNA cancer vaccine targeting melanoma, reducing recurrence risk by 49%. The treatment relies on technologies from Illumina (ILMN), Danaher (DHR), and others. Moderna's stock surged 176.97% on the news, highlighting the shift toward individualized therapies in oncology.

$NTRAMed

Billionaire Stanley Druckenmiller Bought Amazon and Alphabet in Q2. But His Single Biggest Holding Is Neither of Them -- and It's Not Nvidia Either.

Billionaire investor Stanley Druckenmiller's largest Q2 holding was Natera (NTRA), a genetic testing company, not Amazon or Alphabet. Natera reported Q2 2026 revenue of $752.8M, up 39% YoY, and raised full-year guidance to $2.85B-$2.91B. The company's Signatera cancer detection test is a key growth driver, with FDA, PMDA, and EU approvals.